Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Quest Diagnostics Yönetim
Yönetim kriter kontrolleri 4/4
Quest Diagnostics' CEO'su Jim Davis, Nov2022 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 12.67M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.3% maaş ve 90.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.067% ine doğrudan sahiptir ve bu hisseler $ 11.62M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 5.1 yıldır.
Anahtar bilgiler
Jim Davis
İcra Kurulu Başkanı
US$12.7m
Toplam tazminat
| CEO maaş yüzdesi | 9.3% |
| CEO görev süresi | 1.9yrs |
| CEO sahipliği | 0.07% |
| Yönetim ortalama görev süresi | 3.9yrs |
| Yönetim Kurulu ortalama görev süresi | 5.1yrs |
Son yönetim güncellemeleri
Recent updates
These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30
Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Quest Diagnostics Q4 2022 Earnings Preview
Feb 01Quest Diagnostics' unit Pack Health to expand Alabama facility
Jan 17Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 17Returns On Capital Are Showing Encouraging Signs At Quest Diagnostics (NYSE:DGX)
Jan 03An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 46% Undervalued
Dec 04CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$836m |
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
| Sep 30 2019 | n/a | n/a | US$709m |
| Jun 30 2019 | n/a | n/a | US$707m |
| Mar 31 2019 | n/a | n/a | US$720m |
| Dec 31 2018 | US$3m | US$590k | US$733m |
| Sep 30 2018 | n/a | n/a | US$860m |
| Jun 30 2018 | n/a | n/a | US$808m |
| Mar 31 2018 | n/a | n/a | US$782m |
| Dec 31 2017 | US$3m | US$590k | US$769m |
Tazminat ve Piyasa: Jim 'ın toplam tazminatı ($USD 12.67M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 13.04M ).
Tazminat ve Kazançlar: Jim 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Jim Davis (61 yo)
1.9yrs
Görev süresi
US$12,673,834
Tazminat
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 1.9yrs | US$12.67m | 0.067% $ 11.6m | |
| Executive VP & CFO | 2.3yrs | US$3.98m | 0.016% $ 2.7m | |
| Senior VP & General Counsel | 25.2yrs | US$2.25m | 0.040% $ 6.8m | |
| Executive Vice President of Regional Businesses | no data | US$3.16m | 0.058% $ 10.0m | |
| Senior Vice President of Clinical Solutions | 2.2yrs | US$2.02m | 0.012% $ 2.1m | |
| Senior VP | 5.5yrs | Veri yok | 0.032% $ 5.5m | |
| Senior VP | less than a year | Veri yok | Veri yok | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Senior VP & Chief Compliance Officer | 2yrs | Veri yok | Veri yok | |
| Senior VP & Chief Communications Officer | 27.9yrs | Veri yok | Veri yok | |
| Senior VP & Chief Human Resources Officer | 6.7yrs | Veri yok | Veri yok | |
| Senior Vice President of Strategy | 8.7yrs | Veri yok | Veri yok |
3.9yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim: DGX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 1.9yrs | US$12.67m | 0.067% $ 11.6m | |
| Independent Director | 10.8yrs | US$315.44k | 0.023% $ 3.9m | |
| Director | less than a year | Veri yok | Veri yok | |
| Lead Independent Director | 12.8yrs | US$345.94k | Veri yok | |
| Independent Director | 19.8yrs | US$342.12k | Veri yok | |
| Independent Director | 5.7yrs | US$312.33k | 0.0026% $ 444.8k | |
| Independent Director | 10.3yrs | US$315.73k | 0.016% $ 2.8m | |
| Independent Director | 4.6yrs | US$300.44k | Veri yok | |
| Independent Director | 3.2yrs | US$300.44k | Veri yok | |
| Independent Director | 1.4yrs | US$280.41k | Veri yok |
5.1yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: DGX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).